Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.…
Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing
Solid Biosciences (NASDAQ: SLDB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 121 employees.
The shares were at 6.250 USD on 20 November 2026, up 48.3% over 52 weeks. Its 52-week range is 3.790 USD to 11.44 USD: the price is 45.4% below the high and 64.9% above the low.
Its market capitalisation is 697.57M USD.
Solid Biosciences reports return on equity of -96.8% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 329.30M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 18.71 USD is 199.4% above the current price. The next earnings report is expected on 18 March 2027.